NCT04827108

Brief Summary

Cancer is a leading cause of death for children. Chemotherapy is the most common treatment for cancer. Notwithstanding the improved survival, children with cancer still have to face a significant amount of symptoms associated with chemotherapy. Two major symptoms induced by chemotherapy are nausea and vomiting. These two symptoms were demonstrated to cause serious disruption in patients' daily function and quality of life. Given these devastating impacts, intervening children with appropriate methods to alleviate nausea and vomiting during chemotherapy is therefore crucial. It is imperative for nurses to develop non-pharmacological interventions to reduce nausea and vomiting, with the goal of improving the QoL of children with cancer when undergoing chemotherapy First, however, careful assessment of nausea and vomiting in children with cancer is a necessary step towards designing appropriate interventions. This study aims to translate and validate an instrument (PeNAT) which can assess nausea and vomiting among Hong Kong Chinese children and adolescents undergoing chemotherapy

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2022

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 30, 2021

Completed
2 days until next milestone

First Posted

Study publicly available on registry

April 1, 2021

Completed
1.4 years until next milestone

Study Start

First participant enrolled

September 1, 2022

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 28, 2024

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2024

Completed
Last Updated

March 23, 2022

Status Verified

March 1, 2022

Enrollment Period

1.5 years

First QC Date

March 30, 2021

Last Update Submit

March 22, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • The Chinese version of the Pediatric Nausea Assessment Tool (PeNAT) at baseline

    Children will be required to fill in the Chinese version of the Pediatric Nausea Assessment Tool (PeNAT) at baseline. The score ranges from 1 to 4. Higher scores represent a more severe nausea.

    at baseline

Secondary Outcomes (2)

  • The Chinese version of the Pediatric Quality of Life Inventory 4.0 Cancer Module (PedsQL 4.0) at baseline

    at baseline

  • The Chinese version of Center for Epidemiological Studies Depression Scale for Children (CES-DC) at baseline

    at baseline

Interventions

Children will be required to fill in a set of questionnaires including the Chinese version of the Pediatric Nausea Assessment Tool (PeNAT), the Chinese version of the Pediatric Quality of Life Inventory 4.0 Cancer Module (PedsQL 4.0), and the Chinese version of Center for Epidemiological Studies Depression Scale for Children (CES-DC)

Eligibility Criteria

Age4 Years - 17 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

This study targets to recruit 150 subjects from the Hong Kong Children's Hospital. Children who meet the inclusion criteria will be eligible to participate.

You may qualify if:

  • Aged 4 - 17
  • A confirmed diagnosis of cancer
  • Currently undergoing chemotherapy
  • Able to speak Cantonese and read Chinese

You may not qualify if:

  • Cognitive or behavioral problems in medical records

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

NeoplasmsNauseaVomiting

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Katherine Lam, PhD

    The Hong Kong Polytechnic University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Katherine Lam, PhD

CONTACT

Eva Ho, PhD

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Assistant Professor

Study Record Dates

First Submitted

March 30, 2021

First Posted

April 1, 2021

Study Start

September 1, 2022

Primary Completion

February 28, 2024

Study Completion

August 31, 2024

Last Updated

March 23, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share